A predictive survival model for patients with head and neck squamous cell carcinoma treated with immune check point inhibitors

被引：6
作者：
Bonomi, M. [1 ]
Bhateja, P. [1 ]
Issa, M. [1 ]
Klamer, B. [2 ]
Pan, X. [2 ]
Blakaj, A. [3 ]
Karivedu, V [1 ]
Mousa, L. [1 ]
Mitchell, D. [5 ]
Gamez, M. [5 ]
Kang, S. [4 ]
Seim, Nolan B. [4 ]
Old, M. [4 ]
Carrau, R. [4 ]
Rocco, J. [4 ]
Blakaj, D. [5 ]
机构：
[1] Ohio State Univ, Div Med Oncol, Columbus, OH 43210 USA
[2] Ohio State Univ, Dept Biomed Informat, Columbus, OH 43210 USA
[3] Yale Univ, Div Radiat Oncol, New Haven, CT USA
[4] Ohio State Univ, Div Otolaryngol, Columbus, OH 43210 USA
[5] Ohio State Univ, Div Radiat Oncol, Columbus, OH 43210 USA
来源：
ORAL ONCOLOGY | 2020年 / 110卷
关键词：
PD-1; inhibitors; Metastatic; Head and neck cancer; Response; Predictors; Immunotherapy; CANCER; IMMUNOTHERAPY; NIVOLUMAB; RECURRENT; INDEX;
D O I：
10.1016/j.oraloncology.2020.104900
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Background: ICIs have expanded treatment options for HNSCC. A minority of the patients respond to these expensive treatments. Patients and methods: This is a single institutional retrospective review on 121 unresectable or metastatic HNSCC patients treated with ICIs. We predicted that inflammatory markers available through routine blood work, in addition to clinical characteristics may divide patients into groups more or less likely to respond to these agents. Here we develop and internally validate our nomogram to predict survival in patients treated with ICIs.
引用
收藏
页数：6
相关论文
共 46 条
  • [1] Editorial: Advances in Head and Neck Cancer Immunology and Immunotherapy
    Abu Eid, Rasha
    [J]. FRONTIERS IN ONCOLOGY, 2019, 9
  • [2] Prognostic Significance of Hematological Indices in Malignant Melanoma Treated With Immune Checkpoint Inhibitors
    Afzal, Muhammad Z.
    Sarwar, Tayyaba
    Shirai, Keisuke
    [J]. JOURNAL OF IMMUNOTHERAPY, 2019, 42 (07) : 251 - 264
  • [3] [Anonymous], 2018, ONCOLOGY PRO
  • [4] [Anonymous], 2000, APPL LOGISTIC REGRES
  • [5] [Anonymous], **DATA OBJECT**
  • [6] Molecular Profiling of Cohorts of Tumor Samples to Guide Clinical Development of Pembrolizumab as Monotherapy
    Ayers, Mark
    Nebozhyn, Michael
    Cristescu, Razvan
    McClanahan, Terrill K.
    Perini, Rodolfo
    Rubin, Eric
    Cheng, Jonathan D.
    Kaufman, David R.
    Loboda, Andrey
    [J]. CLINICAL CANCER RESEARCH, 2019, 25 (05) : 1564 - 1573
  • [7] IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade
    Ayers, Mark
    Lunceford, Jared
    Nebozhyn, Michael
    Murphy, Erin
    Loboda, Andrey
    Kaufman, David R.
    Albright, Andrew
    Cheng, Jonathan D.
    Kang, S. Peter
    Shankaran, Veena
    Piha-Paul, Sarina A.
    Yearley, Jennifer
    Seiwert, Tanguy Y.
    Ribas, Antoni
    McClanahan, Terrill K.
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2017, 127 (08) : 2930 - 2940
  • [8] Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study
    Bauml, Joshua
    Seiwert, Tanguy Y.
    Pfister, David G.
    Worden, Francis
    Liu, Stephen V.
    Gilbert, Jill
    Saba, Nabil F.
    Weiss, Jared
    Wirth, Lori
    Sukari, Ammar
    Kang, Hyunseok
    Gibson, Michael K.
    Massarelli, Erminia
    Powell, Steven
    Meister, Amy
    Shu, Xinxin
    Cheng, Jonathan D.
    Haddad, Robert
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (14) : 1542 - +
  • [9] A nomogram to predict survival in non-small cell lung cancer patients treated with nivolumab
    Botticelli, Andrea
    Salati, Massimiliano
    Di Pietro, Francesca Romana
    Strigari, Lidia
    Cerbelli, Bruna
    Zizzari, Ilaria Grazia
    Giusti, Raffaele
    Mazzotta, Marco
    Mazzuca, Federica
    Roberto, Michela
    Vici, Patrizia
    Pizzuti, Laura
    Nuti, Marianna
    Marchetti, Paolo
    [J]. JOURNAL OF TRANSLATIONAL MEDICINE, 2019, 17 (1)
  • [10] Baseline neutrophil-to-lymphocyte ratio (NLR) and derived NLR could predict overall survival in patients with advanced melanoma treated with nivolumab
    Capone, Mariaelena
    Giannarelli, Diana
    Mallardo, Domenico
    Madonna, Gabriele
    Festino, Lucia
    Grimaldi, Antonio Maria
    Vanella, Vito
    Simeone, Ester
    Paone, Miriam
    Palmieri, Giuseppe
    Cavalcanti, Ernesta
    Caraco, Corrado
    Ascierto, Paolo Antonio
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2018, 6
12345